Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01107405 · ClinicalTrials.gov registry record · Phase 2
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
A Phase 2 study of Allergic Conjunctivitis, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
- 1
- Study location
NCT01107405 is a Phase 2 study of Allergic Conjunctivitis that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 101 participants, below the 130-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01107405, a Phase 2 study of Allergic Conjunctivitis, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy of loteprednol etabonate ophthalmic base, compared to loteprednol etabonate ophthalmic suspension, and vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in a modified Conjunctival Allergen Challenge model and in an environmental model during pollen season. Comparisons will be made following 2 weeks of dosing.
Conditions Studied
Interventions
- DRUG Loteprednol etabonate base (QD)
- DRUG Loteprednol etabonate base (BID)
- DRUG Loteprednol etabonate base (QID)
- DRUG Loteprednol etabonate suspension
- DRUG Vehicle of loteprednol etabonate
Study Locations (1)
New York
- Bausch & Lomb - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01107405
The ClinicalTrials.gov registry entry for NCT01107405 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (22% lower). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 5 interventions - of which Loteprednol etabonate base (QD) is the first listed.
NCT01107405 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01107405 about?
NCT01107405 is a clinical study titled "Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge". The purpose of this study is to evaluate the efficacy of loteprednol etabonate ophthalmic base, compared to loteprednol etabonate ophthalmic suspension, and vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in a modified Conjunctival Allergen Challenge model and in an en...
What is the current status of trial NCT01107405?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2010-04. Estimated completion is 2010-08.
What conditions does trial NCT01107405 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT01107405?
The interventions under investigation include: Loteprednol etabonate base (QD) (DRUG), Loteprednol etabonate base (BID) (DRUG), Loteprednol etabonate base (QID) (DRUG), Loteprednol etabonate suspension (DRUG), Vehicle of loteprednol etabonate (DRUG).
Who is sponsoring clinical trial NCT01107405?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01107405 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation
COMPLETED · Phase 2
-
Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
COMPLETED · Phase 2
-
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
COMPLETED · Phase 2
-
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.